News | January 06, 2022
Margins under pressure; domestic market growth to slow down: Nirmal Bang
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
Sputnik M is a new member of the Sputnik vaccines family
_256_384.jpg)
In Q2FY22, growth from Covid-driven products in the domestic branded formulation sales should dissipate on a QoQ basis as new covid cases have declined sharply. Vishal Manchanda, research analyst Nirmal Bang gives a preview of pharma companies in this report
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
The first batch will be shipped to the Gamaleya Center for the quality control
The INVANZ brand and generic market had U.S. sales of approximately US $205 million MAT for the most recent twelve months ending March 2021 according to IQVIA Health
Market penetration of Sputnik V will depend on competitive pricing, government orders and the ability to meet soaring demand through timely supply
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)